Drug intelligence / Profile preview

HSVIEAβCMV2

Development stage: Unknown
Modality: Viral Vectors → Gene Addition/Replacement → Gene Therapies
Administration: Subcutaneous

Overview

HSVIEAβCMV2 appears to be a research-stage gene therapy construct, likely utilizing a Herpes Simplex Virus (HSV) vector. The 'IE' component might refer to an Immediate Early promoter, while 'Aβ' strongly suggests a focus on Amyloid-beta, a protein implicated in Alzheimer's disease. The 'CMV2' likely indicates the use of a Cytomegalovirus (CMV) promoter, commonly employed in gene therapy for strong and constitutive gene expression. This construct would theoretically be designed to deliver genetic material to modulate Amyloid-beta pathways, potentially for the treatment of neurodegenerative disorders.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on HSVIEAβCMV2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HSVIEAβCMV2.

Explore the full profile